Trade Names:ReoPro- Injection 2 mg/mL
Binds to glycoprotein IIb/IIIa receptors on surface of platelets, thereby preventing platelet aggregation.
Rapidly binds to glycoprotein IIb/IIIa receptors.
Initial t ½ is less than 10 min. Second phase t ½ is about 30 min.
Platelet function generally recovers over 48 h.
Adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications in patients undergoing PCI and in patients with unstable angina not responding to conventional medical therapy when PCI is planned within 24 h. Intended for use with aspirin and heparin.
Early treatment of MI; treatment of acute ischemic stroke.
Active internal bleeding; recent (6 wk) GI/GU bleeding, major surgery, or trauma; history of cerebrovascular accident (CVA) within the past 2 yr or CVA with significant residual neurological deficit; use of oral anticoagulants within 7 days unless PT is equal to or less than 1.2 times control; thrombocytopenia; severe uncontrolled hypertension; vasculitis; intracranial neoplasm, aneurysm, or arteriovenous malformation; the recent or current use of IV dextran; bleeding diathesis; or hypersensitivity to any component of the product or murine proteins.
IV 0.25 mg/kg bolus 10 to 60 min before PCI followed by continuous infusion of 0.125 mcg/kg/min (to a max of 10 mcg/min) for 12 h.
Patients with unstable angina not responding to conventional medical treatment and who are planning to undergo PCI within 24 h may be treated with 0.25 mg/kg IV bolus followed by an 18- to 24-h IV infusion of 10 mcg/min, concluding 1 h after the PCI.
Store vials at 2° to 8°C (36° to 46°F). Do not freeze. Do not shake. Discard any unused portion.
None well documented.
None well documented.
Hypotension (14%); bradycardia (5%); tachycardia (1%).
Headache (6%); dizziness (3%); anxiety (2%); abnormal thinking (1%).
Increased sweating (1%).
Nausea (14%); vomiting (7%); abdominal pain (3%); dyspepsia (2%); diarrhea (1%).
Anemia (1%); major bleeding (including intracranial hemorrhage), minor bleeding (including gross hematuria, spontaneous hematemesis), thrombocytopenia.
Back pain (18%).
Chest pain (11%); pain (5%); peripheral edema (2%); allergic reactions including anaphylaxis.
If serious bleeding occurs that is not controlled with pressure, stop infusion of abciximab and any concomitant heparin.Platelet counts
Prior to administration, check platelet count, PTT, and APTT. Monitor during and after treatment.
Category C .
Safety and efficacy not established.
Abciximab may cause antibody development. Readministration may be associated with allergic reactions.
Because risk of bleeding is increased, use cautiously, if at all, with thrombolytics, oral anticoagulants, NSAIDs, dipyridamole, and ticlopidine. Institute bleeding precautions.
Monitor platelet counts.
Allergic reactions, including anaphylaxis (sometimes fatal), have been reported.
Care should be taken when attempting vascular access so that only the anterior wall of the femoral artery is punctured.
In the event of serious uncontrolled bleeding or the need for emergency surgery, if platelet function does not return to normal after discontinuing abciximab, it may be restored (at least in part) with platelet transfusions.
Minimize other arterial and venous punctures, epidural procedures, IM injections, and use of urinary catheters, nasotracheal intubation, and nasogastric tubes.
No experience of overdosage in clinical trials.
Copyright © 2009 Wolters Kluwer Health.